Syra Health (SYRA) COO/CFO Prasad Priya Receives Equity Awards

What Happened
Prasad Priya, Syra Health’s Chief Operating Officer, Chief Financial Officer and a director, was granted a package of equity awards on August 31, 2026. The filing shows three derivative awards totaling 173,392 underlying shares: 86,696 performance stock units (PSUs), 60,687 stock options, and 26,009 restricted stock units (RSUs). All awards were reported as acquired at $0.00 (no cash paid at grant). These are grants (not open-market purchases or sales) and do not represent immediately transferable shares—vesting and any exercise requirements will determine future ownership and value.

Key Details

• Transaction date: 2026-08-31; Form 4 filed 2026-09-02 (no late filing indicated in the provided data).
• Awards granted (total = 173,392 underlying shares):
  • 86,696 PSUs (Performance Stock Units) — footnote F1.
  • 60,687 stock options — footnote F2.
  • 26,009 RSUs (Restricted Stock Units) — footnote F3.
• Reported acquisition price: $0.00 for each award (no cash paid at grant).
• Vesting/conditions per footnotes:
  • PSUs (F1): 20% vest each year after grant, contingent on achievement of specified company financial metrics.
  • Options (F2): 20% vest on each Dec 31 in 2027, 2028, 2029, 2030 and 2031.
  • RSUs (F3): 20% vest on each Dec 31 in 2027, 2028, 2029, 2030 and 2031.
• Shares owned after transaction: not specified in the provided filing details.

Context: These are time- and/or performance‑based equity grants. PSUs and RSUs vest into ordinary shares only after vesting conditions are met; options require vesting and then exercise to convert into shares (and typically an exercise payment unless structured otherwise). Grants at $0 simply indicate no cash was paid at grant; the ultimate value depends on Syra Health’s future stock price and achievement of performance/vesting conditions.